Multimodal Approaches to High-Risk Prostate Cancer
The Vancouver Prostate Centre and Department of Urological Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(s2), 33-37; https://doi.org/10.3747/co.v17i0.677
Submission received: 2 June 2010
/
Revised: 6 July 2010
/
Accepted: 5 August 2010
/
Published: 1 September 2010
Abstract
Widespread use of testing for prostate-specific antigen (PSA) has led to a migration in the stage and grade of prostate cancer (PCa), with most men presenting with localized disease. However, 20%–35% of patients still present with high-risk disease (PSA > 20 ng/mL, biopsy Gleason score 8–10, or clinical stage T3). Despite advances in various treatment modalities, patients with high-risk disease have a significant chance of recurrence and death after surgery, often because of the presence of early occult metastasis at time of diagnosis. The optimal management of high-risk pca remains controversial. The present article aims to discuss the traditional approaches and the more recent evolution toward multimodal therapies.
Keywords:
urology; prostate cancer
Share and Cite
MDPI and ACS Style
Koupparis, A.; Gleave, M.E. Multimodal Approaches to High-Risk Prostate Cancer. Curr. Oncol. 2010, 17, 33-37. https://doi.org/10.3747/co.v17i0.677
AMA Style
Koupparis A, Gleave ME. Multimodal Approaches to High-Risk Prostate Cancer. Current Oncology. 2010; 17(s2):33-37. https://doi.org/10.3747/co.v17i0.677
Chicago/Turabian StyleKoupparis, Anthony, and M. E. Gleave. 2010. "Multimodal Approaches to High-Risk Prostate Cancer" Current Oncology 17, no. s2: 33-37. https://doi.org/10.3747/co.v17i0.677
